

# Effects of Dexmedetomidine on Contractility, Relaxation, and Intracellular Calcium Transients of Isolated Ventricular Myocardium

Philippe R. Housmans, M.D., Ph.D.\*

The effects of the highly selective  $\alpha_2$ -adrenoceptor agonist dexmedetomidine on contractility, relaxation, and the intracellular  $\text{Ca}^{2+}$  transients of isolated ventricular myocardium were studied in isolated right ventricular papillary muscles obtained from reserpine-treated ferrets. Dexmedetomidine ( $10^{-10}$ – $10^{-5}$  M) did not alter amplitude and time variables of isometric, isotonic and zero-load-clamped twitches, except for a slight increase in maximal isotonic relaxation rate at  $10^{-5}$  M. Dexmedetomidine ( $10^{-8}$ – $10^{-5}$  M) caused no changes in the intracellular  $\text{Ca}^{2+}$  transient detected with aequorin. These results suggest that dexmedetomidine has no intrinsic myocardial contractile effects. (Key words: Aequorin. Sympathetic nervous system,  $\alpha_2$ -adrenoceptor agonist: dexmedetomidine. Ions: calcium. Heart: contractility, relaxation.)

RECENT STUDIES have shown that a novel, highly specific  $\alpha_2$ -adrenoceptor agonist, dexmedetomidine,<sup>1</sup> produces a hypnotic-anesthetic action in rats<sup>2,3</sup> and reduces halothane MAC in dogs<sup>4</sup> via activation of central  $\alpha_2$ -adrenoceptors.<sup>2</sup> Dexmedetomidine causes a dose-dependent decrease in heart rate and cardiac output in halothane-anesthetized dogs<sup>4</sup> without affecting mean arterial pressure. It is uncertain whether these effects result from a direct effect on the myocardium or from peripheral effects. Therefore, this study was designed to investigate the effects of dexmedetomidine on the intrinsic contractility and relaxation properties of isolated ventricular myocardium.

## Materials and Methods

This study was approved by the Institutional Animal Care and Use Committee.

Twelve papillary muscles of the right ventricle of adult male ferrets were used in this study. The experimental set-up, muscle transducer, recording apparatus, and criteria for selection of suitable preparations were identical to those described earlier,<sup>5</sup> except as noted below. The evening before the experiment, ferrets were given reserpine 5 mg/kg ip to deplete myocardial catecholamines. Ferrets were anesthetized with sodium pentobarbital (100 mg/kg ip), and the heart was quickly excised. Papillary

muscles were mounted vertically in a temperature-controlled muscle chamber (30° C) filled with a physiologic salt solution of the following composition (millimolar concentrations):  $\text{Na}^+$  135,  $\text{K}^+$  5,  $\text{Ca}^{2+}$  2.25,  $\text{Mg}^{2+}$  1,  $\text{Cl}^-$  103.5,  $\text{HCO}_3^-$  24,  $\text{H}_2\text{PO}_4^{2-}$  1,  $\text{SO}_4^{2-}$  1, acetate<sup>-1</sup> 20, and glucose 10. The bathing solution was bubbled continuously with 95%  $\text{O}_2$ –5%  $\text{CO}_2$  (500 ml/min). Muscles were held between a force-length servomechanism transducer (Innovi, Belgium) and a miniature Lucite clip with a built-in stimulation electrode (stimulus interval 4 s, voltage 5% above threshold).

After an initial period of stabilization (2–3 h) during which muscles contracted in alternating series of four isometric and four isotonic contractions, muscle length was set at  $L_{\text{max}}$ , i.e., the length at which active force development was maximal. Each muscle was exposed to tyramine hydrochloride  $10^{-6}$  and  $10^{-5}$  M to ensure that adrenergic nerve endings were depleted of norepinephrine. After the bathing solution was changed, a new series of control contractions was recorded, and each of eight muscles was exposed to cumulative concentrations of dexmedetomidine ( $10^{-10}$ – $10^{-5}$  M in 1 log M unit increments). The bathing solution was changed, and recovery was followed until steady state was achieved, usually after 30–60 min ( $n = 8$ ). In five muscles,  $10^{-6}$  and  $10^{-5}$  M prazosin hydrochloride, an  $\alpha_1$ -adrenoceptor antagonist, was added after exposure to  $10^{-5}$  M dexmedetomidine.

In each of these conditions, variables of contraction and relaxation were recorded. Peak shortening (DL) and




FIG. 1. Cumulative dose-response relationship to dexmedetomidine for developed force (DF) of isometric twitches ( $n = 8$ ). C = control.

\* Assistant Professor of Anesthesiology and Pharmacology.

Received from the Departments of Anesthesiology and Pharmacology, Mayo Foundation, Rochester, Minnesota. Accepted for publication May 22, 1990. Supported in part by United States Public Health Service grant GM 36365. Dexmedetomidine was a gift of Farnos Group Ltd., Turku, Finland.

Address reprint requests to Dr. Housmans: Department of Anesthesiology, Mayo Foundation, Rochester, Minnesota 55905.




FIG. 2. Cumulative dose-response relationship to dexmedetomidine for peak shortening (DL) in isotonic preloaded twitches (n = 8). C = control.

maximal velocity of lengthening (-V) were measured from a preloaded isotonic twitch; maximal unloaded velocity of shortening (MUVS) was determined from a zero-load-clamped twitch; peak developed force (DF), maximal rate of rise of force (+dF/dt), maximal rate of fall of force (-dF/dt), time to peak force (TPF), and time from peak force to half isometric relaxation (RTH) were determined from isometric twitches.<sup>5</sup> Each of these test contractions was separated by seven isotonic twitches at the preload of L<sub>max</sub> to avoid long-term effects of load on contractile state.<sup>6-8</sup>

In four papillary muscles, the intracellular Ca<sup>2+</sup> transient that accompanies contraction was detected with the Ca<sup>2+</sup>-regulated bioluminescent protein aequorin.<sup>9</sup> Aequorin was microinjected into multiple (30-50) superficial cells. Aequorin light emission was detected against a background of total darkness with an EMI 9235QA photomultiplier tube selected for high gain and low dark cur-




FIG. 3. Cumulative dose-response relationship to dexmedetomidine for maximal unloaded velocity of shortening (MUVS) in zero-load-clamped twitches and maximal lengthening velocity (-V) in preloaded isotonic twitches (n = 8). \*\*P < 0.01.




FIG. 4. Cumulative dose-response relationship to dexmedetomidine for maximal rate of rise (+)dF/dt and fall [-dF/dt] of force in isometric twitches (n = 8). C = control.

rent. Light, force, length, and dF/dt signals were recorded continuously on a pen recorder (Honeywell 1400) and on a four-channel digital oscilloscope (Nicolet 4094A). One hundred twenty-eight contractions were recorded to improve the signal-to-noise ratio in light signals.

At each drug concentration, variables were compared with control by means of repeated-measures analysis of variance (ANOVA) and with Duncan's multiple-range test when appropriate. P < 0.05 was considered significant. Data are presented as mean ± SD throughout.

### Results

At the onset of the experiments, tyramine HCl 10<sup>-6</sup> and 10<sup>-5</sup> M did not change any of the measured variables (P > 0.05), except for TPF, which decreased from 257.6 ± 41.0 (control) to 252.0 ± 38.9 ms (tyramine HCl 10<sup>-6</sup> M).





FIG. 5. Cumulative dose-response relationship to dexmedetomidine for time to peak force (TPF) and time to half isometric relaxation (RTH) in isometric twitches, and for time to maximal unloaded velocity of shortening (TMUVS) in zero-load-clamped twitches (n = 8). C = control.

FIG. 6. Cumulative dose-response curve to dexmedetomidine for developed force (top left); for peak shortening (top right); for maximal unloaded velocity of shortening (MUVS) and maximal lengthening velocity ( $-V$ ) (bottom left); and for time to MUVS (TMUVS), time to peak force (TPF), and time to half-isometric relaxation (RTH) (bottom right). After  $10^{-5}$  M dexmedetomidine, muscles ( $n = 5$ ) were exposed to prazosin HCl  $10^{-6}$  M (P) in dexmedetomidine  $10^{-5}$  M. C = control.



Figures 1 and 2 show the changes in DF and DL, respectively, during cumulative dose-response experiments with dexmedetomidine. Even though at  $10^{-5}$  M dexmedetomidine DF and DL were increased over initial control values by  $24.1 \pm 18.9$  and  $14.8 \pm 10.3\%$ , respectively, the changes are not statistically significant. Figure 3 illustrates that MUVS was not affected by dexmedetomidine. Similarly,  $-V$  was not affected significantly until  $10^{-5}$  M dexmedetomidine (a  $47.8 \pm 30.4\%$  increase over control,  $P < 0.01$ ). Figure 4 illustrates the lack of effect of dexmedetomidine on the maximal rates of rise and fall of force. In figure 5, the effects of dexmedetomidine on the time course of contraction and relaxation are illustrated. Dexmedetomidine changed neither TPF of the isometric twitch nor time to MUVS. However, at every concentration tested, dexmedetomidine decreased RTH in a dose-dependent fashion. The maximal abbreviation of isometric relaxation was from  $189.3 \pm 67.3$  (control)

to  $170.3 \pm 59.3$  msec ( $10^{-5}$  M dexmedetomidine), but the changes were not statistically significant.


In five muscles, the addition of prazosin HCl  $10^{-6}$  M in dexmedetomidine  $10^{-5}$  M did not change any of the amplitude or time course variables significantly (fig. 6).

Figure 7 illustrates the isometric twitch and the aequorin signal during a cumulative dose-response experiment to dexmedetomidine ( $10^{-8}$ – $10^{-5}$  M). The aequorin light signals that are representative of the intracellular  $Ca^{2+}$  transient did not change appreciably in dexmedetomidine  $10^{-8}$ – $10^{-5}$  M. Peak isometric force and peak light did not change significantly from control (repeated-measures ANOVA) during exposure to dexmedetomidine  $10^{-8}$ – $10^{-5}$  M (fig. 8).

Discussion

From this study I conclude that dexmedetomidine has no effect on contractility, relaxation, or the intracellular

FIG. 7. Cumulative dose-response curves to dexmedetomidine. The aequorin signal and developed force are displayed in each panel. One hundred twenty-eight contractions were averaged in each drug concentration.






FIG. 8. Effects of dexmedetomidine on peak aequorin light and peak force of isometric twitches ( $n = 4$ ). C = control.

$Ca^{2+}$  transient of isolated ventricular myocardium. Dexmedetomidine is the D-isomer of a novel imidazoline compound that possesses hypnotic-sedative actions, and has a high affinity for  $\alpha_2$ -adrenoceptors.<sup>1</sup>

Recent studies in rats have suggested that central  $\alpha_2$ -adrenoceptors are involved in the hypnotic action of dexmedetomidine.<sup>2</sup> In volunteers, dexmedetomidine decreased systolic and diastolic blood pressure and caused a decrease in heart rate,<sup>10,11</sup> effects that may reflect a decreased sympathetic outflow consequent to activation of central  $\alpha_2$ -adrenoceptors.

In the canine isolated heart-lung preparations, dexmedetomidine had no effect on cardiac function curves,<sup>12</sup> whereas in intact dogs it decreased cardiac output and increased systemic vascular resistance.<sup>4</sup> The decrease in cardiac output has been attributed to 1) the dexmedetomidine-induced bradycardia; 2) an increase in systemic vascular resistance by activation of peripheral  $\alpha_2$ -adrenoceptors; and 3) a decrease in oxygen requirements.<sup>4</sup> Dexmedetomidine has a significant hypnotic-sedative action in doses of 0.5–1.5 mg/kg, which corresponds to approximately  $10^{-7}$  M in humans.<sup>10,11</sup>

At these concentrations, dexmedetomidine had no measurable effects on isolated ferret ventricular myocardium. The lack of effects of this specific  $\alpha_2$ -adrenoceptor agonist is consistent with an earlier observation that rabbit ventricular myocardium lacks functioning  $\alpha_2$ -adrenoceptors.<sup>13</sup> At  $10^{-5}$  M dexmedetomidine, isotonic relaxation velocity was slightly increased, but this may not be physiologically significant.

In conclusion, in clinically useful concentrations, dexmedetomidine has no detectable effects on contractility, relaxation, or the intracellular  $Ca^{2+}$  transient in ferret ventricular myocardium.

I thank S. Guy and L. Wanek for outstanding technical support, and Dr. J. Blinks for his gift of aequorin.

## References

1. Virtanen R, Savola J-M, Saano V, Nyman L: Characterization of the selectivity, specificity and potency of medetomidine as an  $\alpha_2$ -adrenoceptor agonist. *Eur J Pharmacol* 150:9–14, 1988
2. Doze VA, Chen B-X, Maze M: Dexmedetomidine produces a hypnotic-anesthetic action in rats *via* activation of central  $\alpha_2$ -adrenoceptors. *ANESTHESIOLOGY* 71:75–79, 1989
3. Segal IS, Vickery RG, Walton JK, Doze VA, Maze M: Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic  $\alpha_2$ -adrenergic receptor. *ANESTHESIOLOGY* 69:818–823, 1988
4. Vickery RG, Sheridan BC, Segal IS, Maze M: Anesthetic and hemodynamic effects of the stereoisomers of medetomidine, an  $\alpha_2$ -adrenergic agonist, in halothane-anesthetized dogs. *Anesth Analg* 67:611–615, 1988
5. Housmans PR, Murat I: Comparative effects of halothane, enflurane, and isoflurane at equipotent anesthetic concentrations on isolated ventricular myocardium of the ferret: I. Contractility. *ANESTHESIOLOGY* 69:451–463, 1988
6. Parmley WW, Brutsaert DL, Sonnenblick EH: Effects of altered loading on contractile events in isolated cat papillary muscle. *Circ Res* 24:521–532, 1969
7. Kaufmann RL, Lab MJ, Hennekes R, Krause H: Feedback interaction of mechanical and electrical events in the isolated mammalian ventricular myocardium (cat papillary muscle). *Pflügers Arch* 324:100–123, 1971
8. Jewell BR, Rovell JM: Influence of previous mechanical events on the contractility of isolated cat papillary muscle. *J Physiol (Lond)* 235:715–740, 1973
9. Blinks JR, Mattingly PH, Jewell BR, van Leeuwen M, Harrer GC, Allen DG: Practical aspects of the use of aequorin as a calcium indicator: Assay, preparation, microinjection, and interpretation of signals. *Meth Enzymol* 57:292–328, 1978
10. Scheinin M, Kallio A, Koulu M, Arstila M, Viickari J, Scheinin H: Dose-finding and tolerability study of medetomidine in four healthy volunteers. *Current Ther Res* 41:637–646, 1987
11. Kallio A, Karhuvaara S, Scheinin H, Scheinin M: Cardiovascular and sympatholytic effects of intramuscular dexmedetomidine in man (abstract). *ANESTHESIOLOGY* 71:A83, 1989
12. Flacke WE, Flacke JW, McIntee DF, Blow K, Bloor BC: Dexmedetomidine: effects of the  $\alpha_2$  agonist on the isolated mammalian heart (abstract). *ANESTHESIOLOGY* 71:A543, 1989
13. Dukes ID, Vaughan Williams EM: Effects of selective  $\alpha_1$ -,  $\alpha_2$ -,  $\beta_1$ - and  $\beta_2$ -adrenoceptor stimulation on potentials and contractions in the rabbit heart. *J Physiol (Lond)* 355:523–546, 1984